Molecular Partners (NASDAQ:MOLN) Posts Quarterly Earnings Results, Misses Expectations By $0.06 EPS

Molecular Partners (NASDAQ:MOLN) posted its quarterly earnings data on Thursday. The company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.06), FiscalAI reports.

Molecular Partners Stock Performance

Shares of Molecular Partners stock opened at $4.71 on Friday. The company has a fifty day moving average of $4.54 and a 200 day moving average of $4.17. Molecular Partners has a fifty-two week low of $3.36 and a fifty-two week high of $5.36. The company has a market capitalization of $190.19 million, a P/E ratio of -2.45 and a beta of 1.03.

Institutional Trading of Molecular Partners

A hedge fund recently bought a new stake in Molecular Partners stock. SmartHarvest Portfolios LLC bought a new position in shares of Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 12,311 shares of the company’s stock, valued at approximately $54,000. 26.55% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages have commented on MOLN. JPMorgan Chase & Co. lowered their price objective on shares of Molecular Partners from $4.00 to $3.75 and set a “neutral” rating for the company in a research report on Monday, December 8th. HC Wainwright started coverage on shares of Molecular Partners in a research note on Tuesday, January 27th. They issued a “buy” rating and a $13.00 price objective on the stock. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Molecular Partners in a research note on Monday, December 22nd. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Molecular Partners presently has a consensus rating of “Hold” and an average target price of $8.38.

About Molecular Partners

Molecular Partners AG is a clinical-stage biopharmaceutical company headquartered in Zurich, Switzerland, specializing in the design and development of DARPin® (Designed Ankyrin Repeat Protein) therapies. These small, modular proteins are engineered to bind with high specificity and affinity to disease-relevant targets. The company’s technology platform aims to deliver novel treatments across multiple therapeutic areas by leveraging the unique properties of DARPins, including stability, tissue penetration and multi-specific binding capabilities.

The company’s development pipeline spans infectious diseases, ophthalmology and oncology.